Quantcast

Latest Fine-needle aspiration Stories

2014-07-11 08:24:47

New Hybrid Lung Cancer Diagnostic Procedure Shows Significant Cost Savings. ST. LOUIS, July 11, 2014 /PRNewswire/ -- Veran Medical Technologies, a U.S. based medical device company, announced today the positive, cost-effective final results for the initial study of its innovative SPiNPerc(TM) procedure. The SPiNPerc endobronchial percutaneous biopsy study results support the use of a percutaneous approach to biopsy when a traditional bronchoscopic method is not possible. Hospitals,...

2014-07-09 16:26:00

LONDON, July 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Biopsy Devices : Technology and Global Markets https://www.reportbuyer.com/product/2212013/Biopsy-Devices--Technology-and-Global-Markets.html This report provides an in-depth study of the global biopsy devices methods by device, therapautic segments and geographic markets from 2012 through 2018, with five-year CAGR projections from 2013 through 2018. It focuses on vital display technologies...

2014-07-08 23:04:36

Fostering a true team approach with discussions between pathologists, gastroenterologists, and surgeons taking place in live, real-time to collaborate on diagnoses. Melville, New York (PRWEB) July 08, 2014 Remote Medical Technologies, LLC. (RMT) has advanced the iMedHD2™ Telepathology and Ultrasound Systems for use with fine needle aspirations (FNA) and transbronchial needle aspirations (TBNA). The stages in which biopsies are being performed are now changing due to the use of this...

2014-06-26 23:01:59

Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR). Sacramento, CA (PRWEB) June 26, 2014 Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance...

2014-06-23 08:27:52

SOUTH SAN FRANCISCO, Calif., June 23, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today commented on preliminary American Thyroid Association (ATA) guidelines regarding the management of thyroid nodules, which the ATA previewed Friday in a satellite symposium at the ICE/ENDO 2014 meeting in Chicago. "We are very encouraged by these preliminary guidelines as we believe our Afirma® Gene Expression...

2014-06-10 13:39:38

The University of Texas MD Anderson Cancer Center MD Anderson study also highlights surgeon’s influence on patient care, decision-making Needle biopsy, the standard of care radiological procedure for diagnosing breast cancer, is underused with too many patients undergoing the more invasive, excisional biopsy to detect their disease, according to research from The University of Texas MD Anderson Cancer Center. The study, published in the Journal of Clinical Oncology, also finds...

2014-06-03 08:31:46

SOUTH SAN FRANCISCO, Calif., June 3, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the 2014 William Blair Growth Stock Conference on Tuesday, June 10, 2014 at 12:10 p.m. CT in Chicago. The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to the live webcast...

2014-05-22 23:10:25

Oxford-based researchers say cutting-needle biopsy is a safe and effective alternative for patients too frail for thoracoscopy. Raleigh, NC (PRWEB) May 22, 2014 Scientists comparing two methods of obtaining pleural tissue for mesothelioma diagnosis say the less-invasive method may be a good option for certain patients. Details of the study have just been posted on Surviving Mesothelioma and can be read by clicking here. Researchers at the Centre for Respiratory Medicine at Oxford...

2014-05-13 08:31:36

SOUTH SAN FRANCISCO, Calif., May 13, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of its Afirma Malignancy Classifiers to further establish the Afirma Thyroid FNA Analysis as a comprehensive tool for reducing unnecessary surgeries and healthcare costs among the more than 525,000 U.S. patients each year who undergo fine needle aspiration (FNA) biopsies to rule out cancer in thyroid nodules. The Afirma Malignancy Classifiers comprise genomic tests for...

2014-05-07 08:32:27

SOUTH SAN FRANCISCO, Calif., May 7, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced that early data demonstrating the company's ability to develop a molecular classifier differentiating interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), will be presented at the American Thoracic Society (ATS) 2014 International Conference taking place May 16-21, 2014 in San Diego. "We are excited to share our first proof-of-concept data for the development...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related